Despite increasing mergers, hospitals can stay competitive in consolidated markets by utilizing tiered or narrow networks, said Paul B. Ginsburg, PhD, the Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution and a professor of health policy at the University of Southern California.
Despite increasing mergers, hospitals can stay competitive in consolidated markets by utilizing tiered or narrow networks, said Paul B. Ginsburg, PhD, the Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution and a professor of health policy at the University of Southern California.
Transcript (slightly modified)
What tools can payers and others use in consolidated markets to make those markets more competitive despite mergers?
Probably the most powerful tool is narrow networks. Narrow networks have been very popular on the marketplace exchanges, and for good reason, because the premiums they offer are substantially lower than plans with broad networks. So in a sense, insurers have found that that’s a way they can get better prices from providers in a consolidated market, or in an unconsolidated market as well.
There’s something else that’s very much in the news now, is that tiered networks also have a lot of potential to foster competition in consolidated markets. They’ve often been blocked by anti-steering provisions that dominant hospitals have required in their contracts with insurers. Massachusetts had dealt with this by outlawing those provisions. But last week, we learned that the Department of Justice is suing a large system in Charlotte, North Carolina, as … its contracts violate the anti-trust laws. So I’m going to be very excited to watch how that develops.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More